
The FDA approves durvalumab for bladder cancer and gefurulimab for myasthenia gravis, creating distinct ADC, biologic, and autoinjector production needs.
Almac introduces handling and bottling capabilities in EU and US headquarters.
Almac announced that it has expanded its service offering for dispensing and bottling solid dosage products by introducing enhanced containment equipment and processes at its EU and US clinical services sites. The facilities are now in operation following successful installation and validation.
Dr Robert Dunlop, managing director of Almac clinical services said in a






